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Multicenter, randomized phase II trial of CI-1033, an irreversible 
pan- erbB inhibitor, for previously treated advanced non-small cell 
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Purpose: To evaluate the efﬁcacy of the pan-erbB inhibitor, CI-1033, 
in platinum-refractory or recurrent advanced stage non-small cell lung 
cancer.
Patients and Methods: This open label randomized phase II trial 
evaluated CI-1033 in patients with advanced stage NSCLC who failed 
or were refractory to platinum-based chemotherapy. Three oral CI-1033 
doses were evaluated in 21-day dosing cycles - 50 mg daily for 21 
consecutive days; 150 mg daily for 21 consecutive days; and 450 mg 
daily for 14 consecutive days followed by 7 days of no treatment. The 
primary efﬁcacy endpoint was the 1-year survival rate. 
Results: One hundred sixty six patients were randomized. Baseline pa-
tient demographics were well balanced. The most common drug related 
adverse events were rash and diarrhea. The 450 mg arm (14 days on/7 
days off) was closed early due to an excessive rate of adverse events. 
The 1-year survival rates were 29%, 26% and 29%, respectively in the 
3 arms. The response rates were 2%, 2% and 4% and stable disease 
was conﬁrmed in 16, 23% and 18% of patients, respectively in the 3 
study arms. Exploratory analyses demonstrated a prolonged survival in 
patients who developed a rash and in those with baseline tumor ErbB-2 
expression.
Conclusions: CI-1033 had modest activity in unselected NSCLC 
patients but did not meet its primary endpoint. Future studies should 
focus on identifying methods of patient selection.
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EGFR expression in 369 patients surgically treated for non small 
cell lung carcinoma; correlation between gene copy number and 
protein expression
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Background: Lung cancer is one of the most frequently occurring 
neoplastic disorders and overall survival is less than 15%. To identify 
patients with advanced non-small cell lung cancer (NSCLC) likely 
to beneﬁt from treatment with anti-EGFR tyrosine kinase inhibitors, 
EGFR gene copy number determined by ﬂuorescence in situ hybridis-
ing (FISH) and EGFR protein determined by immunohistochemistry 
(IHC) has been used. However, the results have been conﬂicting, and 
as most published studies contains few patients and it is difﬁcult to get 
enough tumour tissue from patients with advanced NSCLC to construct 
high throughput tissue micro arrays (TMA), we studied 369 patients 
surgically treated for NSCLC at the University Hospital of Lund during 
the time periods 1981-83 and 1995-97. There were 151 squamous cell 
carcinomas, 120 adenocarcinomas, 44 large cell carcinomas, 10 small 
cell carcinomas, 26 carcinoids and 18 other tumours. Materials and 
methods: A TMA with three cores from each case was constructed and 
evaluated for EGFR protein expression by IHC and FISH for gene copy 
number. IHC was evaluable for 340 cases. It was scored 0-3+ using 
virtual microscopy with an Aperio Scanscope. Score 0-1+ were consid-
ered as negative and 2-3+ as positive. Also, 342 cases were evaluable 
for gene copy number by FISH and scored as negative; non ampliﬁed 
(NA), and positive; polysomy (usually 4-12 copies of both the EGFR 
gene and chromosome 7) and ampliﬁed. 
Results: IHC; 0+ = 136, 1+ = 64, 2+ = 67, 3+ = 73. All cores contain-
ing viable tumour tissue could be evaluated. Also, hybridizing was 
successful with all cores containing viable tumour tissue; NA = 202 (a 
few cases with trisomy was scored as NA), polysomy = 117, ampli-
ﬁed = 23. Of the cases, 321 pairs were evaluable for both tests and the 
correlation between IHC and FISH was highly signiﬁcant (Wilcoxon, p 
= 0.000000). Survival; In the cohort treated in 1995-97 the overall one 
year survival vas 87%, three year survival 66% and ﬁve year survival 
58%. Of those that survived less than one year, 16/23 (70%) were posi-
tive with FISH compared to 62/149 (42%) of the others (p = 0.012). 
For three and ﬁve year survival no signiﬁcance were reached either 
for FISH or IHC. When data from the 1981-83 cohort was added the 
overall 5 year survival was 50 %. Detailed survival data from the whole 
cohort are in progress! What´s new? This is one of the largest studies of 
EGFR gene copy number in NSCLC. It is also, to our knowledge, the 
ﬁrst study to ﬁnd a highly signiﬁcant correlation between EGFR FISH 
and IHC in NSCLC. This suggest that clinical use of these tests may be 
highly reproducible and can be safely performed before treating patient 
with EGFR tyrosine kinase inhibitors. Other markers such as E-cad-
herin and desmoglein 3 are tested presently.
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Background: Large international randomized trial (ISEL) failed to 
show survival advantage of geﬁtinib over placebo in patients with 
non-small lung cancer (NSCLC) who failed standard chemotherapy. 
However, a subset of patients with NSCLC, especially those of East 
Asian origin, female gender, never-smokers and adenocarcinoma 
respond dramatically well to geﬁtinb. The purpose of this study was 
to evaluate whether geﬁtinib could improve the prognosis of the lung 
adenocarcinoma patients with post-operative recurrence compared with 
other chemotherapeutic agents using a case control study.
